Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J M Haro

Showing results (11-20 of 140) with videos related to

Pageof 14
Sort By:
Progress in Neuro-Psychopharmacology & Biological Psychiatry|May 27, 2008
Predictors of the course of illness in outpatients with schizophrenia: a prospective three year studyJ M Haro, D Novick, D Suarez, et al.
Psychological Medicine|October 28, 2016
Epidemiology of depression with psychotic experiences and its association with chronic physical conditions in 47 low- and middle-income countriesA Koyanagi, H Oh, B Stubbs, et al.
Acta Psychiatrica Scandinavica. Supplementum|May 21, 2003
Unit costs in international economic evaluations: resource costing of the Schizophrenia Outpatient Health Outcomes StudyH Urdahl, M Knapp, E T Edgell, et al.
Schizophrenia Research|July 25, 2006
Estimating the prevalence of schizophrenia in Spain using a disease modelJ L Ayuso-Mateos, P Gutierrez-Recacha, J M Haro, et al.
The Psychiatric Quarterly|February 9, 2011
Complex interaction between symptoms, social factors, and gender in social functioning in a community-dwelling sample of schizophreniaF Vila-Rodriguez, S Ochoa, J Autonell, et al.
European Archives of Psychiatry and Clinical Neuroscience|January 1, 1994
Predictability of rehospitalization for schizophreniaJ M Haro, W W Eaton, W B Bilker, et al.
Pharmacopsychiatry|September 16, 2010
Assessment of medication adherence in a cohort of patients with bipolar disorderA González-Pinto, C Reed, D Novick, et al.
Pharmacopsychiatry|July 9, 2009
Reasons and outcomes of olanzapine dose adjustments in the outpatient treatment of schizophreniaD Suarez, J M Haro, D Novick, et al.
The Journal of Pharmacy and Pharmacology|May 1, 1989
Effects of K+-canrenoate on the development of DOCA-salt hypertensionF Vargas, J M Haro, E Jodar, et al.
Schizophrenia Research|April 12, 2005
Needs and its relation to symptom dimensions in a sample of outpatients with schizophreniaS Ochoa, J M Haro, J Usall, et al.
Pageof 14

Showing results (11-20 of 140) with videos related to

Sort By:
Pageof 14
Progress in Neuro-Psychopharmacology & Biological Psychiatry|May 27, 2008
Predictors of the course of illness in outpatients with schizophrenia: a prospective three year studyJ M Haro, D Novick, D Suarez, et al.
Psychological Medicine|October 28, 2016
Epidemiology of depression with psychotic experiences and its association with chronic physical conditions in 47 low- and middle-income countriesA Koyanagi, H Oh, B Stubbs, et al.
Acta Psychiatrica Scandinavica. Supplementum|May 21, 2003
Unit costs in international economic evaluations: resource costing of the Schizophrenia Outpatient Health Outcomes StudyH Urdahl, M Knapp, E T Edgell, et al.
Schizophrenia Research|July 25, 2006
Estimating the prevalence of schizophrenia in Spain using a disease modelJ L Ayuso-Mateos, P Gutierrez-Recacha, J M Haro, et al.
The Psychiatric Quarterly|February 9, 2011
Complex interaction between symptoms, social factors, and gender in social functioning in a community-dwelling sample of schizophreniaF Vila-Rodriguez, S Ochoa, J Autonell, et al.
European Archives of Psychiatry and Clinical Neuroscience|January 1, 1994
Predictability of rehospitalization for schizophreniaJ M Haro, W W Eaton, W B Bilker, et al.
Pharmacopsychiatry|September 16, 2010
Assessment of medication adherence in a cohort of patients with bipolar disorderA González-Pinto, C Reed, D Novick, et al.
Pharmacopsychiatry|July 9, 2009
Reasons and outcomes of olanzapine dose adjustments in the outpatient treatment of schizophreniaD Suarez, J M Haro, D Novick, et al.
The Journal of Pharmacy and Pharmacology|May 1, 1989
Effects of K+-canrenoate on the development of DOCA-salt hypertensionF Vargas, J M Haro, E Jodar, et al.
Schizophrenia Research|April 12, 2005
Needs and its relation to symptom dimensions in a sample of outpatients with schizophreniaS Ochoa, J M Haro, J Usall, et al.
Pageof 14